SN vs. MXCT, NIOX, EKF, CREO, NCYT, IUG, BELL, IHC, AVO, and RUA
Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include MaxCyte (MXCT), NIOX Group (NIOX), EKF Diagnostics (EKF), Creo Medical Group (CREO), Novacyt (NCYT), Intelligent Ultrasound Group (IUG), Belluscura (BELL), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.
MaxCyte (LON:MXCT) and Smith & Nephew (LON:SN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Smith & Nephew has a consensus price target of GBX 1,346.20, indicating a potential upside of 36.34%. Given MaxCyte's higher possible upside, analysts clearly believe Smith & Nephew is more favorable than MaxCyte.
75.0% of MaxCyte shares are owned by institutional investors. Comparatively, 58.0% of Smith & Nephew shares are owned by institutional investors. 1.2% of MaxCyte shares are owned by company insiders. Comparatively, 0.2% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Smith & Nephew had 3 more articles in the media than MaxCyte. MarketBeat recorded 3 mentions for Smith & Nephew and 0 mentions for MaxCyte. Smith & Nephew's average media sentiment score of 0.67 beat MaxCyte's score of 0.45 indicating that MaxCyte is being referred to more favorably in the media.
MaxCyte has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.
Smith & Nephew has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Smith & Nephew received 405 more outperform votes than MaxCyte when rated by MarketBeat users. However, 68.92% of users gave MaxCyte an outperform vote while only 62.00% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a net margin of 4.74% compared to Smith & Nephew's net margin of -83.00%. MaxCyte's return on equity of 5.02% beat Smith & Nephew's return on equity.
Summary
Smith & Nephew beats MaxCyte on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Smith & Nephew Competitors List
Related Companies and Tools